Nervous Disorder TRIZ Cases

Genotyping CYP2D6, COMT, and transporter genes guides ADHD drug and dose selection to reduce trial and error and side effects.

Acetyl-leucine treatment targets lysosomal storage disorders by reducing lysosomal volume, slowing symptom progression, and improving clinical outcomes.

CSF delivery spreads engineered T cells beyond local injection sites, improving CNS tumor access, persistence, and survival with low toxicity.

Spatially separated growth cues in bifurcated nerve conduits selectively guide motor and sensory regeneration to improve repair and feedback.

Selective purine NR2B modulators improve brain penetration and metabolic stability while reducing dissociative side effects.

Independent cell-adhesive regions in one shared medium enable uniform stem cell seeding and more stable, scalable neural organoid production.

A CBD+CBG composition improves dopaminergic neuron viability and dopamine secretion while avoiding THC-related addiction and side effects.

Uses defective integrase and episomal replication to sustain transient gene expression while avoiding random integration and toxicity.

A small-molecule CD73 inhibitor blocks AMP-to-adenosine conversion to improve specificity and anti-tumor activity in CD73-mediated disease.

A Lactobacillus salivarius composition targets oxidative stress, cytokine imbalance, and gut barrier damage to slow Parkinson's progression.

Using memantine enanthate in a transdermal patch prevents crystal precipitation while improving skin permeability and reducing irritation.

Using fibrillary ApoE to trigger a targeted immune response offers a route to slow or reverse Alzheimer's disease progression.

Small brain-permeable ABCA1 activators directly boost apoE4 lipidation, reduce amyloid β buildup, and avoid peptide delivery limits.

A coenzyme Q10, vitamin D, vitamin B2, PUFA, and choline composition supports neurite outgrowth and reduces neuronal damage after stroke.

Specific phenalkylamine substitutions improve mood disorder treatment while lowering abuse potential through controlled receptor activity and dosing.

Allosteric D3 receptor modulators improve D3 over D2 selectivity, reducing off-target effects in CNS disorder treatment.

Nanonized glutathione stabilized by gamma cyclodextrin and ascorbic acid improves transdermal absorption while limiting oxidation.

A crystalline lemborexant-succinic acid form improves stability, dissolution, and handling through controlled crystallization.

Salting hexylamine with succinic or citric acid reduces odor and toxicity while improving stability, dissolution, and supplement suitability.

A thioic acid ALS therapy case showing how (2S)-2-aminopentanethioic S-acid reduces oxidative stress, paralysis, and motor dysfunction.

Separate layers isolate pyrimidine or purine derivatives from B vitamins to prevent degradation and support higher neuropathy doses.

Fluorescent peptides that bind human nerves give surgeons direct visual guidance, improving nerve identification and reducing damage during surgery.

Selective bicyclic pyridine derivatives activate TAAR1 while limiting dopamine D2 and adrenergic receptor effects in neuropsychiatric therapy.

Graded small-molecule PanK modulation adjusts CoA levels without lethal full deletion, supporting PKAN and diabetes treatment.

Extramuscular botulinum toxin dosing across head and neck nerve zones improves coverage for post-traumatic headache while limiting muscle paralysis.

Neuron-targeted ATP1A3 delivery uses AAV9 vectors and tissue-specific promoters to restore ATPase activity and improve neurological function.

Direct vagus nerve injection of rAAV delivers gigaxonin gene therapy while addressing antibody barriers that limit repeat neurological treatment.

Adjusting dihydroergotamine injection to pH 4.1-4.9 lowers oxidative and isomeric impurities, enabling room-temperature single-dose storage.

Adipose stem cell-derived exosomes deliver anti-inflammatory pain regulators to nerve cells, easing neuropathic pain without stem cell safety risks.

Antibodies that bind pathological alpha-synuclein can inhibit aggregation, block cell-to-cell spread, and support diagnosis in Parkinsonian disorders.

Structural changes to Ariadne analogs preserve 5-HT2A therapeutic action for movement disorders while avoiding hallucinogenic effects.

Non-viral mRNA transfection gives MSCs sustained TGFβ3 expression to improve cartilage repair while avoiding viral safety concerns.

Ionizing radiation pre-treatment boosts HSPC lentiviral transduction at moderate MOI, raising vector copy number while limiting vector use and cost.

Resveratrol analogs block tyrosine or phenylalanine effects on neuronal DNA repair while restoring transcription, protein synthesis, and neuroprotection.

Targeting SENP-1 inhibition helps reduce alpha-synuclein aggregates, oxidative stress, and neuronal damage in neurodegenerative disease treatment.

Small-molecule cycloalkyl carboxylic acid inhibitors target GYS1 to lower tissue glycogen and slow glycogen storage disease progression.

Targeted S1P5 modulation addresses weak neurodegenerative treatment response by supporting oligodendrocyte function and myelin formation.

By binding Aδ and C nerve fibers and cleaving SNAP25, this chimeric neurotoxin blocks CGRP release at the source with fewer side effects.

Reduced-solubility pramipexole xinafoate enables a stable sustained-release suspension that lowers dosing frequency and blood level fluctuation.

Small-molecule PDE5 inhibitors promote autophagy, reduce BACE-1 and Aβ aggregation, and improve intracellular Aβ clearance in Alzheimer’s.

A mixed ethanolamide formula removes cooling, crystallizing, and filtering steps to make high-purity Anandamide more scalable and cost-effective.

Partial agonist and antagonist piperidines target opioid receptor subtypes to preserve pain relief while reducing respiratory depression and dependence.

Exogenous NeuroD1 gene delivery converts reactive astrocytes into neurons, reducing glial scarring and supporting spinal cord and ALS repair.

PGK promoter and WPRE tuning help an AAV frataxin vector reach effective expression across target cells for Friedreich's ataxia treatment.

Blue-light-controlled α-synuclein aggregation in PD hiPSC-derived neurons improves reproducible inhibitor screening and reveals neuroprotective hits.

Direct brain delivery of CD157-positive endothelial cells regenerates blood vessels and helps treat chronic cerebral hypoperfusion.

Blocking SEMA4D with a targeted antibody helps relieve anxiety, memory loss, and motor dysfunction in Alzheimer's disease.

A roughened PTFE repair sheet improves biocompatibility and cell infiltration at nerve injury sites while preserving material stability.

A liquid nutrient blend combines vitamins, minerals, amino acids, and plant extracts to support neurotransmitter pathways with fewer side effects.

A probiotic strain composition reduces corticosterone, endotoxin, and pro-inflammatory cytokines to support depression treatment.

Modifying QS-21 with an oxime group resolves toxicity and stability contradictions while maintaining high adjuvant potency.

Naltrexone upregulates 5-HT3 receptors, improving efficacy while reducing dose-dependent side effects.

Segmented tubular bodies and a hanger component allow dual-sided membrane co-cultivation while preventing air bubble entrapment during handling.

Fenamates modulate ion channels to address underlying disease progression in autism spectrum disorders.

A CAPRIN-1 targeting antibody destroys cancer cells while sparing normal tissue, resolving the contradiction between antitumor activity and side effects.

A TRPA1 calcium channel inhibitor restores normal neuronal activity in the hippocampus.

Fixed-dose herbal composition combining Ginkgo biloba, beta-phenylethylamine, and caffeine to treat psychological disorders.

Switching to water-containing solvents yields stable crystals that overcome difficult filtration and handling qualities.

Carbamazepine lowers toxic protein accumulation through enhanced autophagy, addressing inadequate reduction of aggregates in polymerization disorders.

Segmented delivery bypasses antigen cells, preventing neutralizing antibodies against insulin.

Segmented microvesicles cross the blood-brain barrier to deliver therapeutic signals, resolving tumor risks associated with whole stem cell transplantation.

Anhydrous crystalline INHHQ weakens metal-protein interactions to inhibit aggregation and oxidative processes in neurodegenerative diseases.

Allogeneic mesenchymal stem cells promote neurogenesis and vascular repair through multi-functional cytokine secretion.

Antibodies recognize pathological Tau conformers via localized epitope binding, improving therapeutic specificity without increasing manufacturing complexity.

Segmented erythropoietin peptides provide sustained immunomodulation without cardiovascular complications by utilizing treatment cycles with rest phases.

Engineered hypervariable regions enable antibodies to distinguish K63-linked polyubiquitin from K48-linked forms, resolving detection specificity bottlenecks.

PDE1 inhibitors modulate cGMP hydrolysis in the basal ganglia, addressing unpredictable sleep-wake cycles and dangerous episodes associated with narcolepsy.

A layered pharmaceutical formulation uses a dissolvable intermediate layer to separate multiple drug components.

Segmented camelid single variable domains improve tissue penetration and stability while reducing production costs compared to full monoclonal antibodies.

Small molecule agents disrupt the pathological HIV Tat-BAG3-HSP70 complex, restoring mitochondrial function and reducing hyperphosphorylated tau accumulation.

Fused pyrazole imidazole derivatives resolve Gli1 inhibition specificity and aqueous stability trade-offs.